511 related articles for article (PubMed ID: 28632413)
1. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
Singh SK; Dutta A; Modi G
Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
[TBL] [Abstract][Full Text] [Related]
3. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
Vittorio S; Adornato I; Gitto R; Peña-Díaz S; Ventura S; De Luca L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1727-1735. PubMed ID: 32924648
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration.
Wang X; Becker K; Levine N; Zhang M; Lieberman AP; Moore DJ; Ma J
Acta Neuropathol Commun; 2019 Mar; 7(1):41. PubMed ID: 30871620
[TBL] [Abstract][Full Text] [Related]
5. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Yasuda T; Mochizuki H
Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
[TBL] [Abstract][Full Text] [Related]
6. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning.
Horne RI; Andrzejewska EA; Alam P; Brotzakis ZF; Srivastava A; Aubert A; Nowinska M; Gregory RC; Staats R; Possenti A; Chia S; Sormanni P; Ghetti B; Caughey B; Knowles TPJ; Vendruscolo M
Nat Chem Biol; 2024 May; 20(5):634-645. PubMed ID: 38632492
[TBL] [Abstract][Full Text] [Related]
8. Gangliosides, α-Synuclein, and Parkinson's Disease.
Ledeen RW; Wu G
Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.
Diepenbroek M; Casadei N; Esmer H; Saido TC; Takano J; Kahle PJ; Nixon RA; Rao MV; Melki R; Pieri L; Helling S; Marcus K; Krueger R; Masliah E; Riess O; Nuber S
Hum Mol Genet; 2014 Aug; 23(15):3975-89. PubMed ID: 24619358
[TBL] [Abstract][Full Text] [Related]
10. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
11. Coordination and redox properties of copper interaction with α-synuclein.
Valensin D; Dell'Acqua S; Kozlowski H; Casella L
J Inorg Biochem; 2016 Oct; 163():292-300. PubMed ID: 27112900
[TBL] [Abstract][Full Text] [Related]
12. Pathological role of lipid interaction with α-synuclein in Parkinson's disease.
Suzuki M; Sango K; Wada K; Nagai Y
Neurochem Int; 2018 Oct; 119():97-106. PubMed ID: 29305919
[TBL] [Abstract][Full Text] [Related]
13. Cofilin 1 promotes the aggregation and cell-to-cell transmission of α-synuclein in Parkinson's disease.
Yan M; Meng L; Dai L; Zhang X; Chen G; Zheng Y; Zha Y; Zeng Y; Zhang Z
Biochem Biophys Res Commun; 2020 Sep; 529(4):1053-1060. PubMed ID: 32819564
[TBL] [Abstract][Full Text] [Related]
14. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and structure-activity evaluation of novel 2-pyridone-based inhibitors of α-synuclein aggregation with potentially improved BBB permeability.
Mahía A; Peña-Díaz S; Navarro S; José Galano-Frutos J; Pallarés I; Pujols J; Díaz-de-Villegas MD; Gálvez JA; Ventura S; Sancho J
Bioorg Chem; 2021 Dec; 117():105472. PubMed ID: 34775206
[TBL] [Abstract][Full Text] [Related]
16. New insights into cellular α-synuclein homeostasis in health and disease.
Dettmer U; Selkoe D; Bartels T
Curr Opin Neurobiol; 2016 Feb; 36():15-22. PubMed ID: 26282834
[TBL] [Abstract][Full Text] [Related]
17. Ignored avenues in alpha-synuclein associated proteopathy.
Chowhan RK; Mittal S; Dar TA; Kamal MA; Singh LR
CNS Neurol Disord Drug Targets; 2014; 13(7):1246-57. PubMed ID: 25230221
[TBL] [Abstract][Full Text] [Related]
18. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of α-synuclein aggregation within liquid condensates.
Dada ST; Toprakcioglu Z; Cali MP; Röntgen A; Hardenberg MC; Morris OM; Mrugalla LK; Knowles TPJ; Vendruscolo M
Nat Commun; 2024 May; 15(1):3835. PubMed ID: 38714700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
